Clinical Trials Logo
Clinical Research
NCT ID: NCT04176809 Recruiting - Clinical trial for Breast Cancer

Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer

COMPLIANCE
Start date: May 14, 2021
Phase: N/A
Study type: Interventional

Only 59% of women with breast cancer (BC) treated with Endocrine Therapy (ET) remain compliant one year upon initial prescription, despite its proven effectiveness in reducing recurrence and improving survival. Health-related quality of life (HRQoL) in BC has been widely studied and the positive effects of its routine evaluation on the improvement of communication between patients and medical staff and survival have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Since compliance is a multidimensional phenomenon, a multifaceted intervention is necessary to improve it. Thus, the investigators hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with delivery of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC.

NCT ID: NCT04172753 Recruiting - Clinical trial for Breast Cancer

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.

NCT ID: NCT04158843 Recruiting - Clinical trial for Breast Cancer

Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis

BOMB
Start date: May 9, 2020
Phase: N/A
Study type: Interventional

A Randomized, Open Label, Phase III Trial to Evaluate Radical Local Treatment versus Palliative Treatment for Breast Cancer Patients with Primary Ipsilateral Humerus or Sternum Oligometastasis